A0. Diversifying the TB vaccine pipeline (general/other)

PA-01: Versatility of the CoPoP platform for antigen discovery and tuberculosis vaccine testing
Andres Obregon-Henao, Colorado State University (USA)
Abstract | Poster

PA-02: TBVAC-HORIZON: Investigating lung immunity to accelerate the development of innovative tuberculosis vaccines
Helen McShane, University of Oxford (UK)
Abstract | Poster

PD03: Development of a human lung-liver-lymph node co-culture on a chip for the screening of tuberculosis vaccine candidates
Elly van Riet, TBVI (Netherlands)
Abstract

PD04: Investigating the role of Indoleamine dioxygenase in modulating immune responses to Mycobacterium tuberculosis
Smriti Mehra, Texas Biomedical Research Institute (USA)
Abstract

PD05: A multi-antigen subunit vaccine improves BCG efficacy in mice and non-human primates
Elena Stylianou, University of Oxford (UK)
Abstract

PD06: BAXERNA: Developing a next-generation mRNA vaccine against TB
Lyudmila Kovalchuke, VIB-UGent (Belgium)
Abstract | Poster

PD07: Mucosal vaccination with cyclic dinucleotide adjuvants induces effective T cell homing and IL-17-dependent protection against Mycobacterium tuberculosis infection which may be autophagy
Isabel D Lamb-Echegaray, UC Berkeley (USA)
Abstract

A1. Mechanisms of biomarkers and protection

PD08: Recombinant BCG vaccine rBCG-LTAK63 enhances autophagy in innate immune cells
Ana Carolina de Oliveira Carvalho, Instituto Butantan (Brazil)
Abstract

PA10: Coexpression network analysis-based identification of critical genes and regulatory factors driving inter-individual variation in response to Mycobacterium tuberculosis infection
Oluwaseun Oluwatosin Taofeek, Crescent University (Nigeria)
Abstract | Poster

A2. Novel approaches to vaccine discovery

PA-11: Genetic modification of BCG by CRISPR technology for DIVA skin test compatibility in bovine tuberculosis control
Luana Moraes, Instituto Butantan (Brazil)
Abstract

PA-12: Comparative analysis of endogenous CRISPR/Cas and DNA repair associated-genes in mycobacteria: towards genetic manipulation for development on TB vaccines.
Paulo Silveira, Instituto Butantan (Brazil)
Abstract

A3. Improved formulations and delivery platforms

PA-13: Designing sequences of novel Mtb antigens for mRNA delivering platforms
Nawamin Pinpathomrat, University of Oxford (UK)
Abstract

PA-14: A promising mucosal protein vaccine against tuberculosis
Rocio Zuazo, CONICET (Argentina)
Abstract | Poster

PA-15: Immunogenicity and protective efficacy of mRNA-LNP technology against in vivo Mtb infection
Chris De Voss, University of Oxford (UK)
Abstract

PA-16: A self-assembling and self-adjuvanting multiepitope peptide nanoparticle vaccine improves the efficacy and immunogenicity of Bacille Calmette-Guérin
Guangzu Zhao, James Cook University (Australia)
Abstract | Poster

A4. Human challenge model/Controlled human infection model

PD-17: Characterising lung mucosal and systematic immune response in an aerosol BCG human challenge model using single cell sequencing
Shuailin Li, University of Oxford (UK)
Abstract

PD-18: A phase I single site open label clinical trial for the development of a human BCG challenge model to assess TB drugs and vaccines
Elizabeth Church, Fred Hutchinson Cancer Center (USA)
Abstract

PD-19: Prior BCG vaccination protects against subsequent aerosol BCG challenge in UK adults
Iman Satti, University of Oxford (UK)
Abstract

A5. Preclinical development

PD-20: A Mycobacterium tuberculosis variable antigen vaccine induces infection tolerance
Zach P Howard, University of California, San Francisco (USA)
Abstract | Poster

PA-21: T cell responses to TITAN mRNA vaccine antigens in adults with Mtb infection and TB disease
Monika M Looney, University of Cape Town (South Africa)
Abstract | Poster

PA-22: Generation and testing of human-ready, rationally attenuated and efficacious live M. tuberculosis vaccine candidates to protect against tuberculosis and TB/HIV co-infection
Garima Arora, Texas Biomedical Research Institute (USA)
Abstract

PA-24: Development of TB recombinant mycobacterial vaccine without antimicrobial resistance marker
Ana Paula Junqueira-Kipnis, Federal University of Goiás (Brazil)
Abstract | Poster

PA-25: Developing a Novel mRNA vaccine for tuberculosis: Insights from in silico analysis
Juliana Gil Melgaço, Bio-Manguinhos/Fiocruz (Brazil)
Abstract

A6. Optimizing animal models

PD-27: Establishing a humanized mouse model to mimic human tuberculosis pathology for in vivo immunotherapy research
Monalisa Martins Trentini, Instituto Butantan (Brazil)
Abstract

PA-28: Prior Mycobacterium tuberculosis exposure enhances the efficacy of subunit vaccination
Sara B. Cohen, Seattle Children's Research Institute (USA)
Abstract

PA-29: Microevolution of BCG vaccine strain after inoculation in susceptible individuals may lead to increased virulence of mycobacteria
Bárbara A. Barcelos Rangel, State University of Northern Fluminense (Brazil)
Abstract

PA-30: Refinement of aerobiology techniques for the pre-clinical evaluation of interventions against respiratory pathogens
Rebecca Winsbury, UK Health Security Agency (UK)
Abstract

Track B0: Accelerating clinical development (general/other)

PA-31: Lessons from COVID-19 Vaccine Development for Accelerating TB Vaccine Research
Yumna Moosa, Africa Health Research Institute (South Africa)
Abstract | Poster

PA-32: Accelerating TB vaccine development by “planning for success”: The MTBVAC phase 2b clinical trial to prevent TB in African adolescents and adults
Lewis K Schrager, IAVI (USA)
Abstract | Poster

B1. Clinical trials

PD-33: Community consensus and call to action on inclusion of pregnant and breastfeeding women and persons in TB vaccine trials
Edna Tembo, Coalition of Women Living with HIV/AIDS (COWLHA) (Malawi)
Abstract | Poster

PD-34: The ethics of including persons deprived of liberty in tuberculosis vaccine trials
Monica Queiroz Ferreira de Magalhaes, Rutgers University (USA)
Abstract | Poster

PD-35: Perceptions of the incarcerated population regarding tuberculosis research and vaccines
Crhistinne C M Gonçalves, Faculdade de Medicina da Universidade Federal do Mato Grosso do Sul (Brazil)
Abstract | Poster

PA-36: MTBVAC202: Defining the dose for a multi-centre Phase 3 efficacy trial in infants
Michele Tameris, University of Cape Town (South Africa)
Abstract | Poster

PA-37: MTBVAC dose-finding study, a Phase 1b/2a randomized, controlled, double-blind clinical trial, in young adults in South Africa, with and without sensitization to Mycobacterium tuberculosis
Angelique Luabeya Kany Kany, University of Cape Town, South Africa
Abstract

B2. Trial site capacity

PA-38: QuantiFERON-Plus (QFT-plus) positivity in a large preventive treatment trial among people living with HIV (PLHIV) in 3 high TB-burden settings: implications for vaccine development in PLHIV
Dinis Bento Nguenha, Centro de Investigação em Saúde de Manhiça (CISM) (Mozambique)
Abstract

PA-39: Integrated clinical research center selection for phase 2b MTBVAC TB prevention efficacy trial in African adolescents and adults
Puck T Pelzer, IAVI (Netherlands)
Abstract | Poster

PA-40: MTBVAC vaccine: Challenges in establishing phase III trial capacity in Antananarivo
Arimanitra Razafimahefa, Institut Pasteur de Madagascar (Madagascar)
Abstract | Poster

PA-41: Sex differences in Mycobacterium tuberculosis immunoreactivity risk in Blantyre, Malawi: a community-based prevalence survey
Mphatso D Phiri, Malawi-Liverpool-Wellcome Clinical Research Programme (Malawi)
Abstract 

PA-42: Pre-screening protocol to identify HIV and TB infection and reduce costs of screening healthy adults for first in human TB vaccine trials in Gauteng, South Africa
Vaneshree Govender, The Aurum Institute NPC (South Africa)
Abstract | Poster

B3. Trial endpoints

PA-43: Electronic diaries for reactogenicity self-reporting: Experience of a rural South-African site
Anne Derache, Africa Health Research Institute (South Africa)
Abstract

B4. Correlates of protection
PD-44: mRNA signatures measured prior to H56:IC31 vaccination predict TB relapse in HIV negative adults successfully treated for drug-susceptible pulmonary TB
Simon C Mendelsohn, University of Cape Town (South Africa)
Abstract

Track C0: Ensuring public health impact (general/other)

PA-45: Navigating the unknown: Ensuring equitable TB vaccine access to maximize health impact
Rupali J Limaye, Johns Hopkins Bloomberg School of Public Health (USA)
Abstract | Poster

PA-46: BCG vaccine in children and development of tuberculosis: it has a real protective effect in endemic population
Juliana Monteiro, Aggeu Magalhães Institute/Oswaldo Cruz Foundation (Brazil)
Abstract | Poster

PA-47: Tuberculosis in Brazil: A historical view from the local BCG vaccine manufacturer
Luiz Roberto Castello Branco, Fundação Ataulpho de Paiva/ Fundação Oswaldo Cruz (Brazil)
Abstract

PA-52: Potential implications of reduced tuberculosis vaccine efficacy in those with undernutrition on overall vaccine impact in India
Rebecca A Clark, London School of Hygiene and Tropical Medicine (UK)
Abstract

C1. Demand assessments

PA-49: A scoping review of studies on new and repurposed TB vaccine implementation in high burden settings
Joeri Buis, KNCV Tuberculosis Foundation (Netherlands)
Abstract | Poster

PA-50: Evolution of Tuberculosis Vaccine Modelling studies: Insights from studies in India
Ruchita Jalal, IAVI (India)
Abstract | Poster

C2. Delivery systems

PD-51: Enhancing community engagement in tuberculosis vaccine delivery among key populations: A qualitative study
Martha N Nyakambi, PHDA (Kenya)
Abstract | Poster

C3. Vaccine value proposition

PA-53: The implications of using different time horizons when evaluating investment to prevent infectious disease
Rebecca A Clark, London School of Hygiene and Tropical Medicine (UK)
Abstract | Poster

C4. Barriers and enablers of vaccine uptake

PD-54:Willingness to receive a future TB vaccine among pregnant women living in Brazil, Ghana, Kenya, and Pakistan 
Rupali J Limaye, Johns Hopkins Bloomberg School of Public Health (USA)
Abstract | Poster

PA-55: Insights into TB vaccine acceptability among adolescents in Khayelitsha through a public engagement lens
Anastasia Sideris Koch, Eh!woza (South Africa)
Abstract | Poster

PA-56: Acceptability of a novel TB vaccine or BCG booster among adults, caretakers of adolescents and adolescents in Manhiça District, southern Mozambique.
Alberto Garcia-Basteiro, Manhica Health Research Center (CISM), Mozambique
Abstract | Poster

D0. Preparing for implementation (general/other)

PA-57: New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?
Rebecca Clark, London School of Hygiene and Tropical Medicine (UK)
Abstract

D1. Policy pathways

PA-58: Preparing the landscape for TB vaccines: South Africa’s strategic planning
Waasila Jasat, National Department of Health (South Africa)
Abstract | Poster

D2. Procurement planning

PA-59: Forecasting TB vaccine demand to support supply and procurement planning
Jessy Joseph, IAVI (India)
Abstract | Poster

E0. Enabling conditions for TB vaccine development (general/other)

A-60: The TB Vaccine Advocacy Roadmap (TB Vax ARM): A global case study of advocacy best practice
Shaun Palmer, IAVI (Netherlands)
Abstract | Poster

E2. Open science

PA-64: Leveraging the multi-country Ubuntu COVID-19 vaccine clinical trial as a platform for tuberculosis biomarker research in sub-Saharan Africa
Asa Tapley, Fred Hutchinson Cancer Center (USA)
Abstract | Poster

PA-65: Biospecimens from tuberculosis cases and controls in a healthy adult HIV vaccine trial cohort in South Africa
Elizabeth Chandler Church, Fred Hutchinson Cancer Center (USA)
Abstract

E3. Political commitment

PA-61: Financing and policy innovation to advance TB vaccines through licensure: A G20 policy proposal
Shaun Palmer, IAVI (Netherlands)
Abstract | Poster